




Cost Effectiveness Analysis of Riluzole for ALS in 
























A thesis  
presented to the University of Waterloo 
in fulfillment of the  
thesis requirement for the degree of  
Master of Science 
in 














I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, 
including any required final revisions, as accepted by my examiners.   





Objective: To identify the factors associated with the prescription of riluzole and assess its 
cost-effectiveness for patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) in long 
stay home care in Ontario, Canada.  
Method: A retrospective cohort study was conducted using the Ontario Association of 
Community Care Access Centres – Home Care (OACCAC-HC) data. Assessment records of 
ALS patients admitted into home care between April 1
st
, 2005 and March 31
st
, 2013, who had 
information on whether or not they used riluzole, were reviewed. Univariate and multiple 
logistic regressions analysis were used to identify the predictors influencing the receipt of 
riluzole. Variables included in the analyses were chosen in correlation to the prognostic 
factors identified in the literature review. For the cost-effectiveness analysis, cost data were 
obtained from relevant literatures and published information on Canadian Institute for Health 
Information Patient Cost Estimator accounting for the cost of administration of riluzole, 
standard supportive home care services, and cost-savings from delay in hospitalization. 
Effectiveness was measured using time to discharge from home care due to death, placement 
into long-term care, and hospitalization, controlling for potential confounding variables using 
propensity score stratification. The incremental cost-effectiveness ratio was calculated based 
on time spent in different states and the associated utility scores using the stratified 
population and expressed as cost per life-year gained and quality-adjusted life-year gained. 
Sensitivity analyses included one-way deterministic sensitivity analysis to investigate the 
change in ICER due to variations in specific input parameters. Scenario analyses were 
developed to depict the ICERs in best and worst case scenarios.   
Resuts: The total study population comprised of 1,351 patients diagnosed with ALS, of 
which 1,277 patients had information on the use of riluzole. In the multiple logistic regression 
analysis, older age, moderate – moderate severe impairment in cognitive functions, not being 
married and geographical locations across LHINs (Champlain, Erie St. Clair, Hamilton 
Niagara Haldimand Brant, Mississauga Halton, North East, South East, and South West) 
decreased the likelihood of riluzole prescription. Primary analysis showed that treatment with 
riluzole was associated with prolonged survival in home care [HR = 0.86; 95% confidence 
interval: 0.745 – 0.99; p=0.046]. Survival gain associated with riluzole was 1.5 months, while 
the incremental cost was approximately $5,000 per patient. Thus, the incremental cost-
effectiveness ratio of riluzole versus standard supportive home care services was $41,128.85 
per life-year gained or $55,579.53 per quality-adjusted life-year gained. One-way 
deterministic sensitivity analysis suggested an ICER ranging from $50,000 – 78,000 per 
QALY, while scenario analyses depicting best and worst case scenarios suggested an ICERs 
of $29,890.36 per QALY and $106,641.52 per QALY. 
Conclusion: Patient characteristics such as age, cognitive score, geographical location and 
marital status markedly influenced drug utilization of riluzole. In addition, the findings of this 
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study indicate that riluzole has a borderline or unfavorable cost-effectiveness for patients 
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Chapter 1: Introduction 
Amyotrophic Lateral Sclerosis (ALS) is a chronic degenerative disease involving 
upper and lower motor neurons with no known etiology (Klein & Forshew, 1996). The 
progressive loss of muscle strength and pulmonary function eventually leads to death, which 
is most commonly caused by respiratory muscle failure (Ginsberg & Lowe, 2002). The 
survival time can vary significantly between individuals; however, an average survival time is 
between 2 to 5 years after initial diagnosis (Radunovic, Annane, Jewitt, & Mustfa, 2010).  
Currently, riluzole is the only approved medication to treat ALS. Despite its modest 
survival benefits, the drug is known to represent a significant economic burden for patients 
and caregivers. Cost-effectiveness studies have attempted to identify factors driving the costs 
of treatment along with measurement of survival benefits associated with riluzole, however, 
lack of long-term data have limited the accuracy of stage-specific cost and survival estimates 
within different care settings (Home Care, Nursing Home, Complex Continuing Care). Based 
on the length of stay in different care facilities, the costs involved in the overall treatment as 
well as the quality of life of patients can significantly differ. As riluzole is known to prolong 
and maintain patients’ health status in mild to moderate stage (Bensimon & Lacomblez & 
Meininger, 1994), it is important to accurately assess the delays in transitions to other care 
settings in order to fully understand how the drug affects the cost of care as well as the 
quality-of-life in ALS patients.  
Using Ontario Association of Community Care Access Centres – Home Care 
(OACCAC-HC) assessments, which collects person-level data on various demographic and 
clinical variables with discharge information, along with cost estimations derived from 
previous economic burden studies of ALS, this proposed study will contribute to previous 
findings by measuring survival benefits using observational data. It will also produce reliable 
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direct cost estimates associated with the use of riluzole to determine its cost-effectiveness 
specific to the Canadian context.  
Chapter 2: Literature Review 
 
2.1 Overview of ALS 
Clinical Features 
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder 
with no known etiology or cure (Klein & Forshew, 1996). ALS affects both upper and lower 
motor neurons in the brain and the spinal cord, causing progressive loss of voluntary motor 
activity (speech, swallowing, and respiratory function) and muscle weakness, which results in 
nearly all patients developing dysphagia, excessive salivation and weight loss (Ginsberg & 
Lowe, 2002). Eventually, patients will become dependent on others to carry out their daily 
activities, and ultimately may require enteral feeding, hospice care, tracheostomy, and 
mechanical ventilation in order to sustain life. Majority of deaths associated with ALS is due 
to respiratory failures, and death usually occurs within 2 to 5 years after onset of symptoms 
(Radunovic et al., 2010).  
 
Classification 
 Epidemiological and genetic factors allow ALS to be classified into two categories. 
In approximately 90–95 percent of all ALS occurrences, the disease occurs at random with no 
associated risk factors (Kiernan et al., 2011). This form of ALS is classified as classical 
sporadic ALS. Patients with sporadic ALS have no family history of ALS, and their family 
members are not considered to be at risk of developing ALS throughout their lifetime 
(Kiernan et al., 2011).   
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 On the other hand, approximately 5-10 percent of all ALS occurrences are inherited 
and thus classified as familial ALS. This form of ALS stems from a pattern of inheritance in 
which one parent carries the gene responsible for the disease (Kiernan et al., 2011). One third 
of all familial ALS and small percentage of sporadic ALS are linked to a defect in a gene 
known as “chromosome 9 open reading frame 72” or C9orf72 (Mizielinska & Isaacs, 2014). 
Moreover, 20 percent of all familial ALS incidences are linked to a mutation of copper zinc 
superoxide dismutase 1 (SOD1) in chromosome 21 (Siddique & Deng, 1996).    
  
Epidemiology 
 ALS is most common for people aged between 40 to 75 years old (Miller et al, 2000). 
While the disease is relatively rare, it still affects thousands of people worldwide, with 
country-specific prevalence ranging from 1-10 cases per 100,000 population and average 
prevalence of 7/100,000 population worldwide (Ginsberg & Lowe, 2002). Crude incidence 
rate of ALS ranges between 0.3 and 2.6 cases per 100,000 population, with an average crude 
incidence of 1.75/100,000 population worldwide (Ginsberg & Lowe, 2002). It has been 
previously indicated that males are more vulnerable to ALS with an overall ratio of about 1.5 
men to every woman (Tsai, Wang, Hwang, Lee, & Lee, 2015). Current trends suggest that 
incidence of ALS is increasing globally due to increases in longevity and improved 
diagnostic capabilities (Kahana & Zilber, 1984).  
 
Symptoms and Diagnosis 
 As ALS is progressive in nature, symptoms and signs become more apparent as the 
disease progresses from the onset. There are 4 stages to ALS. As patients consecutively shift 
from one stage to another, symptoms gradually worsen altogether and ultimately result in 
death. Descriptions of stages of ALS along with the supportive care required in each stage 
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can be found in Appendix A. ALS patients may often require a comprehensive team of doctors 
and specialists to manage the symptoms. Specialists involved in the management of ALS 
might include: neurologists; physiatrists; nutritionists; gastroenterologists; occupational 
therapists; respiratory therapists; speech language therapists; social workers; infectious 
disease specialists; mental health professionals; nurses; personal support workers and an 
internist (Munsat, Riviere, Swash & Leclerc, 1998). Moreover, research suggests that the 
median duration of time spent in any stage was 10.9 months (95% CI 10.4 – 11.4) (Balendra 
et al., 2014).  
 There is no single laboratory test or procedure that could confirm the diagnosis of 
ALS. Hence, a series of clinical procedures and diagnostic tests are conducted to rule out 
other neurological diseases that do not conform to the symptoms of ALS (Chio, 1999). 
Comprehensive diagnostic tests include, but are not limited to: electromyography (EMG), 
nerve conduction study (NCS), spinal tap, X-rays, magnetic resonance imaging (MRI), 
muscle biopsy, genetic tests, and blood and urine tests (Klein & Forshew, 1996) 
 
Medication 
 Riluzole (6-(trifluoromethoxy) benzothiazol-2-amine) is the only FDA-approved 
drug for the treatment of ALS (Messori et al., 1999). First developed as an antiepileptic agent 
by Rhône-Poulenc Rorer in France, the drug currently has no other indication except than for 
the treatment for ALS. As part of the class of antiglutamates, riluzole works by inhibiting the 
release of a compound called glutamate that is known to injure nerve cells (Ginsberg & Lowe, 
2002). Riluzole will not fully cure ALS; however, it can prolong life and delay the need for 




) was first approved by The Food and Drug Administration (FDA) 
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in 1995, and since then, Rilutek has been used to treat ALS for nearly 20 years (full summary 
of history of Rilutek
®
 can be found in Appendix B). Results from the double-blind, placebo-
controlled efficacy trials of riluzole showed that use of riluzole (100mg daily) provides only 
moderate survival effect and prolongs life by approximately two months (Lacomblez, 
Bensimon, Meininger, Leigh & Guillet, 1996; Miller, Mitchell, Lyon & Moore, 2003). The 
results indicate that patients treated with riluzole remained in moderate health state longer 
than patients treated with placebo, and significantly slowed down the deterioration of muscle 
strength (Bensimon et al., 1994). A summary of the two randomized clinical trials of riluzole 
is shown in Table 1.  
 It has been recommended that patients receive an initial dosage of 50 mg/day and 
after a week, the dosage should be increased to 100 mg/day (50 mg every morning and 
evening) on an empty stomach (Ginsberg & Lowe, 2002). Studies have found that 100 
mg/day delivered optimal results, while increasing the dosage to 200 mg/day had no 
additional benefits (Ginsberg & Lowe, 2002; Gray, 1998).  
Previous research suggests that riluzole is more effective in the earlier stages of ALS, 
with bulbar-onset patients having more beneficial effects than limb-onset patients (Zoccolella 
et al., 2007). Moreover, patients over the age of 70 years old who were prescribed to riluzole 
had 8 months longer median survival time and reduction in mortality rate at 12 months by 
27%, regardless of site of symptom onset (Zoccolella et al., 2007).  
To date, no study has investigated the prevalence of use of riluzole, specifically in 
home care setting. Furthermore, the drug utilization of riluzole, as well as characteristics 




Table 1: Summary of randomized clinical trials of Riluzole 
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2.2 Prognostic Factors 
 
2.2.1 Demographic Factors 
Age 
Majority of studies have found that age at the time of diagnosis or symptom onset is a 
major prognostic factor in ALS, with decrease in survival time in correlation to increase in 
age (Louwerse, Visser, Bossuyt, & Weverling, 1997; Preux et al., 1996; Stambler, Charatan & 
Cedarbaum, 1998; Testa, Lovati, Ferrarini, Salmoiraghi & Filippini, 2004; Uebayashi, Yase, 
Tanaka, Shimada & Toyokura, 1984). A diagnosis of ALS at younger ages is associated with 
longer survival and slower disease progression, even after adjustments for possible 
confounding factors associated with age (Czaplinski, Yen & Appel; 2006; Czaplinski, Yen, 
Simpson & Appel, 2007). Patients diagnosed before 40 years of age have a median survival 
time of 6.01 years (95% CI 4.67-7.34), often surviving over 10 years, compared with median 
survival time of 3.23 years (95% CI 3.03-3.43) for patients diagnosed between 40 and 70 
years old and 2.85 years (95% CI 2.47-3.23) for patients over 70 years old (Czaplinski et al., 




Previous studies have identified that there is no association between gender and 
prognosis (Czaplinski et al., 2006; McCombe & Henderson, 2010). While male patients have 
a greater likelihood of developing symptom onsets in the spinal regions whereas female 
patients tend to develop symptom onsets in the bulbar region, gender had no clear effect on 
survival (McCombe & Henderson, 2010). This finding is odd considering that majority of 
patients diagnosed with ALS are males (approximately 60%). However, some investigators 
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have found that shorter survival time was observed among women (Aguila, Longstreth, 
McGuire, Koepsell & Belle, 2003).  
 
Psychosocial Factors  
Psychosocial factors are important prognostic factors that have direct relationship 
with quality of life and survival in ALS patients. A longitudinal study that assessed 10 
psychometric variables (hopelessness, depression, loneliness, perceived stress, anger 
expression, purpose-in-life, locus of control, life rating, social support, coping methods) 
observed that survival curves were significantly different between high and low 
psychological score groups (McDonald, Wiedenfeld, Hillel, Carpenter & Walter, 1994). 
Research suggests that patients with psychological distress have a 6.76-fold increased risk of 
mortality and a 2.24-fold increased risk of dying in any given time period in comparison to 
patients with psychological well-being (McDonald et al., 1994). Moreover, a cross-sectional 
study assessing the determinants of quality of life in ALS patients has found that quality of 
life associated with ALS is not dependent upon one’s physical status, but rather relies mainly 
on psychological and supportive factors (Chio et al., 2004). Therefore, it is important for 
clinicians not to overlook psychological factors and thereby provide structured psychosocial 
interventions to both patients and caregivers in order to improve quality of life and survival in 
the course of the disease management.  
 
2.2.2 Clinical Factors 
Site of Onset 
ALS is usually manifested through weakness in upper limb, lower limb, or bulbar 
musculature. In 75-80% of patients, symptoms begin with weakness in limb involvement 
(limb-onset patients), while 20-25% of patients begin with difficulty swallowing or eating 
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due to weakness of the tongue or pharyngeal muscles (bulbar-onset patients) (Turner et al., 
2009).    
Previous studies have reported that disease onset in the bulbar muscles is associated 
with shorter survival time in comparison to limb/spinal onset (3.74 years vs 2.80 years, 
p<0.001) (Czaplinski et al., 2006; Testa et al., 2004; Uebayashi et al., 1984). Bulbar-onset 
patients have faster decline rate of respiratory functions, malnutrition, and dehydration 
(Louwerse et al., 1997). Bulbar symptoms are an independent prognostic factor, which 
indicates that presence of bulbar functions at any point of the disease is a predictive factor of 
shorter survival outcome. On the other hand, patients with limb symptoms at onset have 
slower disease progression and longer survival (Czaplinski et al., 2006; Stambler et al., 1998). 
Within limb symptoms, research suggests that lower limb onset is associated with poorer 
prognosis due to an increased risk of thromboembolic disease and infections from declined 
rate of motility in comparison to upper limb onset (Preux et al., 1996; Uebayashi et al., 1984). 
However, one study has identified that poorer prognosis was observed among patients with 
upper limb onset (Magnus et al., 2002). While it is clear that bulbar-onset patients have 
shorter survival than limb-onset patients, more research on limb-onset patients is necessary in 
order to fully understand the prognostic effects in lower and upper limb onsets.  
 
Delay in Diagnosis 
The time delay between symptom onset and first diagnosis was a strong indicator of a 
better prognosis. The delay is negatively related to hazard, meaning that the longer the delay, 
the longer the survival and the slower the disease progression (Aguila et al., 2003; 
Haverkamp, Appel & Appel, 1995; Stambler et al., 1998). While exact association is 
unknown, investigators have suggested that time between symptom onset and first diagnosis 
is likely to indicate the initial rate of disease progression, meaning short time delay is likely 
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to indicate a more aggressive disease that requires more rapid medical attention whereas 
patients with slower disease progression are accustomed to initial symptoms for longer period 
of time before they seek medical care (Aguila et al., 2003; Haverkamp et al., 1995; Lee, 
Annegers & Appel, 1995).   
 
Cognitive Functions 
Patients and their caregivers are often told that ALS has no association with one’s 
cognition; however, recent findings suggest that ALS patients develop progressive cognitive 
impairments (Lomen-Hoerth et al., 2003; Ringholz et al., 2005; Strong et al., 1999). Previous 
research suggests that cognitive impairments are present in 50% of all ALS patients and 
implicate executive dysfunction and mild memory decline during the disease progression 
(Laird, Studenski, Perera & Wallace, 2001). Approximately 5-10% of ALS patients develop 
frontotemporal lobar dementia (FTLD), and half of all patients have deficits in temporal and 
frontal executive functions (Lomen-Hoerth et al., 2003). Moreover, it has been found that 
bulbar-onset ALS patients with cognitive impairments developed greater severity of 
neuropsychological dysfunctions (Ringholz et al., 2005; Strong et al., 1999). One study has 
also found that ALS patients with FTLD have shorter survival than those without executive 
function deficits (Armon & Brandstater, 1999). While exact reasons are unknown, it is 
hypothesized that patients with FTLD have poor compliance with mechanical ventilation and 
percutaneous endoscopic gastrostomy (PEG) (Chio et al., 2012; Olney et al., 2005).  
  
Respiratory Functions 
As most deaths with ALS are associated with respiratory failure, respiratory function 
is an important determinant of outcome in patients with ALS. Conditions such as sleep 
disruption, hypopneas, orthopnea, and REM-related desaturation are common with declining 
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strengths of respiratory muscles (Bourke, Shaw & Gibson, 2001). Research suggests that 
forced vital capacity (FVC %) at the time of initial diagnosis was the most relevant predictor 
of outcome in ALS (Chio et al., 2002; Czaplinski et al., 2006; Stambler et al., 1998). 
Predicted vital capacity (VC %) and decline of VC % has shown to be correlated with overall 
survival time of patients (Chio et al., 2002; Czaplinski et al., 2006; Lyall, Donaldson, Polkey, 
Leigh & Moxham, 2001). Moreover, non-invasive sniff nasal pressure (SNP) has greatest 
predictive power, as it can accurately assess respiratory muscle strengths and its 
corresponding likelihood of ventilatory failure, but not for patients with significant bulbar 
involvement (Lyall et al., 2001).  
 
Nutrition 
The occurrence of malnutrition in patients with ALS is an independent prognostic 
factor and is significantly correlated with worsened survival (Desport et al., 1999; Desport et 
al., 2000). Malnutrition is primarily caused by swallowing dysfunction due to involvement of 
the lower sets of cranial nerves and is present in 16-50% of ALS patients (Desport et al., 
2000). Nutrition status is assessed by calculating Body Mass Index (BMI) and BMI below 
18.5-20 kg/m
2
 indicates status of malnutrition (Desport et al., 2000). A prospective study 
assessing nutrition status and survival indicates that survival was worse for malnourished 
patients, with a 7.7-fold increased risk of death (Desport et al., 1999). Hence, constant 




 Falls are independent predictors of adverse outcomes in ALS (Gil et al., 2008). 
Previous research suggests that approximately 2% of all deaths in ALS patients are falls 
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related (Rubenstein & Josephson, 2002). Previous research has identified numerous risk 
factors associated with falls such as muscle weakness, deficits in balance, visual deficits, 
arthritis, impairments in ADLs, signs of depression, and cognitive impairment (Ringholz et 
al., 2005). 
 
2.3 Economic Impact of ALS 
For the purpose of convenient comparison of economic impacts associated with ALS, 
all costs mentioned in this section have been converted to US currency rate as of September 
2016 to adjust for inflation, and using US Inflation Calculator published by the latest US 
government Consumer Price Index (CPI) data.  
 
Cost of Illness 
In the US, Larkindale et al. estimated the total annual per-patient costs to be $63,693 
for patients with ALS. The estimated costs are associated with direct medical, nonmedical, 
and indirect costs. Using Medicare claims data to estimate direct medical costs and cost-of-
illness survey to estimate nonmedical costs and indirect family income loss, the study 
estimated $32,148 for annual direct costs, $18,479 for nonmedical costs and $15,166 for 
indirect family income loss. The study identified that ALS patient costs are significantly 
associated with use of wheelchairs and mechanical ventilators.  
The costs estimated by Larkindale et al., are higher than those estimated by Klein & 
Forshew., who estimated the costs of diagnosing ALS as between $15,338 to $30,675 
depending on the types of procedures such as laboratory tests, electrophysiology, 
neuroimaging, and neuropathology. Moreover, augmentative communication equipment 
varied greatly in costs, ranging from $38 for an eye-blink board to $30,675 for computer 
system with ALS-specific software. Total cost per year for nutritional maintenance costs were 
 
13 
estimated to be $9,200 excluding PEG tube surgery, which costs $2,300. Highest costs 
associated with ALS were seen as the disease progressed into terminal end-stage with costs of 
mechanical ventilation around $305,985 per year, which is driven mostly by the nursing care 
costs (16 hours/day) of $23,000 per month or $276,077 per year. 
In the United Kingdom, Munsat et al. assessed the economic burden of ALS by 
measuring direct health service costs in relation to the disease progression. All costs were 
estimated based on interviews of four neurologists specializing in the treatment of ALS. Costs 
included hospitalization, physician time, inpatient and outpatient laboratory examinations, 
medical procedures and drug therapy, where prices were determined from the NHS Trust 
Tariffs for 1996-1997, standard published prices and the Drug Tariff for 1996-1997. Total 
cost for each ALS health state was measured by applying unit costs to the resources utilized 
in different stages of the disease. Total annual costs for ALS patients ranged from $2,495 to 
$1,683 for mild and moderate state and $3,574 to $6,585 for severe and terminal state 
respectively. The relatively low annual cost for moderate state was due to reductions in 
hospitalization in this particular state, whereas patients in mild state were likely to be 
hospitalized for diagnostic related purposes. Nevertheless, the estimated costs presented in 
this study are significantly lower compared to other studies, especially in terminal state as the 
cost of mechanical ventilation was not considered for this study. The justification provided by 
the author states that at the time of the study, expert neurologists did not offer ventilation to 
patients in their normal clinical practice and thus, it was not discussed in the interviews. 
Athanasakis et al. investigated the economic burden of ALS in Greece from a 
societal perspective by taking direct and indirect costs into considerations. Direct costs were 
obtained from retrospective review of patient records during the period of 2012-2013 that 
included the costs of medications, physician consultations, diagnostic tests, hospitalizations, 
rehabilitation care and medical equipment. Indirect costs were obtained from patient 
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interviews that collected lost productivity from work absenteeism and value of informal care 
by caregivers. However, the author notes that values of indirect costs were estimated through 
national minimum wage and thus, the estimated costs do not reflect full accuracy. Total 
annual costs per patient was $10,311 in which direct costs accounted for 57.8% or $5,958 and 
indirect costs accounted for the remaining 42.2% or $4,353. While the estimated figure is 
relatively lower compared to results from other countries, the author notes that lower cost per 
patient is largely due to lower prices for medications, lower tariffs for healthcare and low 
wage levels.  
Gladman, Dharamshi, and Zinman quantified the economic burden of ALS patients 
and their families by exploring both direct and indirect costs in Canada. Both of the cost 
components were derived from structured interviews with 50 consecutive ALS patients and 
their family members. Direct costs consisted of out-of-pocket and government/NPO 
supported expenses and included costs for home renovation, mobility aids, medical costs, 
private physical therapy, occupational therapy, and personal social worker services. Indirect 
costs consisted of income lost due to job loss, permanent disability, early retirement, and any 
unpaid work absence of patient or their family members. Results have shown that average 
annual direct cost per patient was $25,285.30 of which $15,305.51 was paid out-of-pocket. 
The average annual indirect cost per patient and their family members were $44,430.10. The 
author notes, however, that the study is not generalizable across all ALS patients across 
Canada as the population that has been captured in this study is derived only from Ontario.  
 Comparison of economic burden across the studies indicates that costs ranges vary 
significantly across different countries. This is likely due to units included in direct costs, 
indirect costs, and nonmedical costs. Moreover, the differences in normal clinical practices 
across different countries, states, and provinces may have affected the units included in direct 
costs. In addition, the prices of health services provided across different healthcare systems 
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would attribute to the difference in the cost range. Nevertheless, all studies mentioned in this 
section indicate that costs associated with ALS increases as the disease approaches terminal 
state. Hence, the economic burden of ALS is heavily dependent upon the severity of the 
disease.   
 
Cost Effectiveness 
 Cost-effectiveness analysis is a method of economic evaluation, which compares 
both cost and health benefits of different interventions. Cost-effectiveness analysis is a useful 
tool to guide the decision-making process for allocating resources with a limited budget.   
 The basic calculation of CEA involves dividing the difference in costs of intervention 
by the difference in health gain measured in natural units. Cost-effectiveness is often 
expressed as an incremental cost-effectiveness ratio (ICER) according to the formula: 
 
Where CT is the mean costs associated with the new intervention and CC is the mean costs 
associated with the comparison intervention. Likewise, ET and EC are the mean effectiveness 
associated with new and comparison intervention respectively. If ∆C is negative and ∆E is 
positive, the new intervention is said to be “dominant” as the new intervention is clearly cost-
effective as it is associated with less costs and more clinically effective. Similarly, if ∆C is 
positive and ∆E is negative, the new intervention is not cost-effective or “dominated” as it is 
both more costly and less clinically effective. When ICER is calculated, it is compared with a 
threshold value, also known as willingness to pay threshold. The thresholds are higher in 
developed countries than developing countries. Should the ICER for the new intervention fall 
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below the threshold value, the new intervention is recommended to be implemented over the 
existing comparator.  
Costs associated with CEA are measured in financial monetary values. On the other 
hand, health benefits can be measured in various units, such as life years gained (LYG), 
quality-adjusted life years (QALY), or disability-adjusted life years (DALY) (Robinson, 
1993). 
A literature review was conducted for cost-effectiveness analysis of riluzole by 
searching PubMed and Scopus. Articles related to the costs and clinical effectiveness of 
riluzole for ALS was searched. The full search strategy used for this review can be found in 
Appendix C. Only peer reviewed journals were included in this review and thus, other sources 
including but not limited to conference abstracts, reports, errata, manufacturer’s reports, 
letters, editorials, and book chapters were excluded. Furthermore, study types other than 
economic evaluations, or articles written in languages other than English were excluded.  
 To date, only a handful of economic evaluations were ever conducted to assess the 
cost effectiveness of riluzole for ALS. All studies included in this review were conducted in 
Europe using health services perspective. Moreover, all studies used 18 months duration of 
base data (tracheostomy-free survival) to estimate survival rate. All cost-effectiveness studies 
in this literature review have been based on results from the two major double-blind placebo-
controlled trials (Bensimon et al., 1994; Lacomblez et al., 1996). Variety of methods for 
estimating survival has been used across the four studies, which include Eyeball, Gompertz, 
Weibull and Markov models.  
The findings across the four studies included in the literature review showed mixed 
evaluations of riluzole regarding its cost-effectiveness. All studies universally reported a 
positive survival gain associated with the use of riluzole (0.041 – 6.3 months). Two studies 
established that riluzole is a cost-effective treatment with ICER per LYG of $18,027 and 
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$28,451 (Ginsberg & Lev, 1997; Tavakoli et al., 2001). However, the remaining two studies 
reported riluzole as not cost-effective with ICER per LYG of $73,416 and $90,514 (Gray, 
1998; Messori et al., 1999). The full summary of the studies in this literature review are 
shown in Table 2.  
Common limitations across all studies were the uncertainties that remained for the 
economic and survival analysis due to the lack of long term clinical data and utility 
measurements. Moreover, none of the studies has incorporated home care services or other 
community services in either the survival or cost component, which are significantly 
associated with greater extension of survival, quality of life and economic burden for the 
management of ALS.  
Previous research suggests that the proportions of ALS patients in home care, nursing 
homes, and complex continuing care in Ontario are 69.5%, 11.8%, and 18.7%, respectively 
(Kehyayan et al., 2014). Due to the progressive nature of the disease, the survival estimates 
and costs associated with ALS in different care facilities vary widely and thus, it is 
important that cost-effectiveness studies are conducted using stage-specific estimates 
accounting for different care settings in order to answer the many uncertainties that exist in 
the previously published studies and better understand the benefits associated with the use 
of riluzole.  
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Chapter 3: Study Rationale 
As pointed out in the literature review section of this thesis, variations in direct costs 
across different health care systems and survival analysis have presented limitations in 
producing accurate estimates of cost-effectiveness. Hence, the purpose of this study was to 
improve on the existing cost-effectiveness analyses by conducting survival analysis from 
observational data that contains a larger sample size than the conventional RCTs that have 
been previously used by other studies and estimating accurate costs per QALY gained based 
on information regarding delays in care transition. 
Traditionally, CEA has heavily relied upon RCTs to evaluate the clinical efficacy of 
drugs. However, in rare conditions such as ALS where the sample size is limited and 
conducting trials for long period of time may be unfeasible, observational studies may be 
more useful for assessing the long term effects associated with riluzole. Survival gains from 
previous research have been estimated from truncated databases with a high degree of 
uncertainty and thus, observational data was required to fill this gap by providing more 
accurate stage-specific survival gains.  
 The main advantage for this study was the use of the OACCAC-HC data, which 
include person-level clinical assessments along with discharge information for each patient to 
accurately measure the delay in care transition associated with the use of riluzole. Moreover, 
cost estimation from the Canadian Institute for Health Information further expanded on direct 
cost data beyond the existing scope of previous literatures, which improved the understanding 





3.1 Research Questions:  
1. What are the factors influencing prescription of riluzole for ALS patients? 
2. Is riluzole a cost-effective intervention for ALS? 
 




 Despite the fact that riluzole is the only medication available, drug utilization 
patterns across patients living with ALS are unclear. There have been no previous studies 
conducted to identify the factors associated with the prescription of riluzole.  
 Thus, the objective of this component of the study was to identify and explore the 
factors influencing the prescription of riluzole for people living with ALS. As there are no 
clear systematic guidelines determining the prescription candidacy for ALS patients, the 
present study offers a unique opportunity to investigate the key determinants affecting 
prescription decisions, which will contribute to the understanding of prescribing patterns of 
riluzole in Ontario  
 
4.2 Methods 
Design, Sample and Setting 
This study was conducted as part of a retrospective cohort study evaluating the cost-
effectiveness of Riluzole for ALS in Ontario Home Care using the Ontario Association of 
Community Care Access Centres – Home Care (OACCAC-HC) data. The OACCAC-HC 
database houses interRAI’s RAI-HC assessments of long stay home care clients within each 
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of the Ontario Local Health Integration Networks (LHINs). RAI-HC is a standardized 
comprehensive assessment instrument, which captures information regarding patients’ 
sociodemographic characteristics, mental health status, clinical status, psychosocial status, 
physical functions, medication use, and receipt of specific services. Since 2002, the RAI-HC 
assessment has been mandated for all long-stay home care clients with assessment data 
captured in OACCAC database. The RAI-HC assessments are conducted approximately 
twice per year.  
Embedded within the RAI-HC are scales that provide validated summary measures 
of individual functioning in specified clinical areas. In this study, six validated scales that 
summarize functional status in cognition, ADLs, health instability, pain, and mood were 
examined. The corresponding scales are Cognitive Performance Scale, Activities of Daily 
Living Self-Performance Hierarchy Scale, Instrumental Activities of Daily Living 
Involvement Scale, Changes in Health, End-Stage Disease and Signs and Symptoms Scale, 
Pain Scale, and Depression Rating Scale. 
Cognitive Performance Scale (CPS) is a combined measurement of memory 
impairments, level of consciousness, decision-making skills, and the ability to be understood 
by others (Morris et al., 1994). The scores range from 0 (intact) to 6 (very severe impairment). 
Previous studies have reported that CPS is highly correlated to the Mini-Mental State Exam 
(MMSE), which is a widely used test for cognition status that has been found to be both valid 
and reliable (Morris et al., 1994).  
 Activities of Daily Living (ADL) Self-Performance Hierarchy Scale measure one’s 
physical functioning (e.g. dressing, eating, bathing, locomotion, etc.) using selected ADL 
items that represent stages of the disablement process. The scores range from 0 (independent) 
to 6 (total dependence), with the additional option where the activity did not occur (8), which 
is also coded as total dependence. While the ADL Self-Performance Hierarchy Scale was 
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originally developed for use in the nursing homes, the instrument was proven valid and 
reliable in home care setting as well (Landi et al., 2000).  
 The Instrumental Activities of Daily Living (IADL) Involvement Scale is similar to 
ADL Hierarchy Scale as the instrument also measures one’s self-maintenance abilities. 
However, instead of measuring one’s physical functions, the Involvement Scale assesses 
functioning in routine activities around the home or in the community. The scale is composed 
of seven items: meal preparation, ordinary housework, managing finances, managing 
medications, phone use, shopping and transportation. These items are then summed to 
produce a score that ranges from 0 to 48 with higher scores indicating greater impairments.  
 The Pain Scale was developed using the Visual Analogue Scale (VAS) as the external 
standard due to its sensitivity of assessing multiple levels of pain (Fries, Simon, Morris, 
Flodstrom, & Bookstein, 2001). The scale assesses two items, which are pain frequency and 
pain intensity. In total, there are four levels, which are no pain (0), less than daily pain (1), 
daily pain but not severe (2), and daily severe pain (3).  
The Depression Rating Scale (DRS) is composed of seven RAI-HC mood items, 
which are used for clinical assessments to screen for depression. These items are summed 
together to produce a score which ranges between 0 (no mood symptoms) to 14 (all mood 
symptoms present). Scores of 3 or greater indicates major or minor depressive disorders. The 
scale was validated against the Hamilton Depression Rating Scale and the Cornell Scale for 
Depression, which are the current standard scales used for psychiatric research and dementia 
respectively (Burrows et al., 2000)  
The Changes in Health, End-Stage Disease and Signs and Symptoms (CHESS) Scale 
was developed to detect health instability and identify individuals at risk for serious decline 
in functions. The scale assesses nine items which include worsening of decision-making, 
decline in ADL, vomiting, edema, shortness of breath, end-stage disease, weight loss, 
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dehydration, and leaving food uneaten. These items are summed to produce a 6-point scale, 
which ranges from 0 (not at all unstable) to 5 (highly unstable). The scale has been validated 
to be highly predictive of adverse outcomes such as mortality, hospitalization, pain, caregiver 
stress, and poor self-rated health (Hirdes, Frijters, & Teare, 2003). 
The University of Waterloo retains de-identified copies of OACCAC database as part 
of a license agreement between interRAI and CIHI. Previous studies and reviews have found 
RAI instruments to be valid and reliable measures of patient characteristics. (Hirdes, Poss, 
Mitchell, Korngut & Heckman, 2014; Hirdes et al., 2008; Kim et al., 2015)  
The population that has been examined in this study is Ontario long stay home care 
clients (received service for 60 days or longer) diagnosed with ALS in the province of 
Ontario. Individuals receiving acute or palliative care do not receive RAI-HC assessments 
and rather, receive RAI-PC assessment and thus, these individuals are not included in this 
dataset. RAI-HC assessments for home care clients were collected between January 2002 and 
March 2015. However, from close consultation with a RAI data specialist, ALS patients with 
RAI-HC assessment data from April 1
st
, 2005 to March 31
st
, 2013 were included in this study 
to compensate for the errors during the initial implementation period and in correlation to the 
2-year follow-up period that was used for this study. Moreover, patients who were diagnosed 
with ALS, but had no information on medication use of riluzole were excluded from the study. 
If the client had multiple assessments in that period, only the baseline assessment was used 
for the analyses in combination with information on the reason for discharge from home care. 
Approximately 60% of the study population had multiple assessments. Furthermore, patients 
who had a history of receiving a tracheostomy were not included in the study.   





 Data for diagnosis, outcome, exposure, and other clinical assessment variables were 
drawn from the OACCAC-HC database. The dependent variable for this study was the 
prescription of riluzole at the time of initial RAI-HC assessment. All the variables that have 
been included in the model were chosen in correlation to the prognostic factors derived from 
review of relevant literatures. Independent variables that were thought to be the predictors of 
outcome and included in this study were: age, gender, geographical location, marital status, 
availability of caregiver at the time of referral, food consumption, difficulty in swallowing, 
falls frequency, pressure ulcers, stair climbing, stamina, Cognitive Performance Scale, 
Activities of Daily Living Hierarchy Scale, Instrumental Activities of Daily Living 
Involvement Scale, Pain Scale, Depression Rating Scale, and Changes in Health, End-Stage 
Disease, Signs, and Symptoms Scale. 
 
Statistical Analyses 
 All statistical analyses for this study were conducted using Statistical Analysis 
Software (SAS), Version 9.4, SAS Institute Inc, Cary, North Carolina, USA. To identify 
predictors of riluzole prescription, univariate logistic regressions were completed to estimate 
the odds ratio for each potential predictor. Variables that reached statistical significance (p 
<0.05) in the univariate analysis were included in the multiple logistic regression. Variables 
included in the multiple logistic regression were: age, gender, marital status, geographical 
locations, and Cognitive Performance Scale.  
 
4.3 Ethics Approval 
 This project was cleared for ethics by the Office of Research Ethics at the University 





 From a total of 1,351 patients diagnosed with ALS, 1,277 patients had information on 
the use of riluzole. Demographics of study participants are summarized in Table 3.   
 
Table 3: Demographic characteristics of the study population 
Baseline Characteristics No-Riluzole 
(n = 776) (%) 
Riluzole 
(n = 501) (%) 




18– 45 36 (5%) 34 (7%) 
46 – 55 91 (12%) 75 (15%) 
56 – 65 194 (25%) 159 (32%) 
66 – 75 244 (31%) 151 (30%) 
>75 211 (27%) 82 (16%) 
Gender   
Male 401 (52%) 290 (58%) 
Female 375 (48%) 211 (42%) 
Marital Status (Married)   
Not Married 267 (34%) 126 (25%) 
Married 509 (66%) 375 (75%) 
Availability of Caregiver   
Living Alone 132 (17%) 68 (14%) 
Living with spouse or others 644 (83%) 433 (86%) 
Geographical Location   
Central East 70 (9%) 76 (15%) 
Central 75 (10%) 89 (17%) 
Champlain 111 (14%) 26 (5%) 
Central West 28 (4%) 25 (5%) 
Erie St. Clair 43 (5%) 18 (4%) 
Hamilton Niagara Haldimand Brant 87 (11%) 48 (10%) 
Mississauga Halton 69 (9%) 46 (9%) 
North East 53 (7%) 22 (4%) 
North Simcoe Muskoka 26 (3%) 18 (4%) 
North West 15 (2%) 8 (2%) 
South East 47 (6%) 18 (4%) 
South West 79 (9%) 37 (7%) 
Toronto Central 44 (6%) 46 (9%) 
Waterloo Wellington 38 (5%) 24 (5%) 
Overall, study participants were more likely to be males than females, with majority 
being over 55 years of age. More than half of the study populations were not taking riluzole 
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at the time of the initial assessment. The mean age was 67 years old in the non-riluzole group 
and 63 years old in the riluzole group. The proportions of subjects who were married were 
higher in the riluzole group than the non-riluzole group. Clinical characteristics of both 
groups are summarized in Table 4. Both groups appeared to have very similar clinical status 
at the time of the initial assessment.  
Table 4: Summary of Clinical Characteristics 
Baseline Characteristics No-Riluzole 
(n = 776) (%) 
Riluzole 
(n = 501) (%) 
Weight Loss   
No 580 (75%) 390 (78%) 
Yes 196 (25%) 111 (22%) 
Food Consumption: Ate one or 
fewer meals in at least 2 of the last 
3 days 
  
No 734 (95%) 468 (93%) 
Yes 42 (5%) 33 (7%) 
Difficulty Swallowing   
No 398 (51%) 256 (51%) 
Yes 378 (49%) 245 (49%) 
Falls   
No 351 (45%) 227 (45%) 
Yes 425 (55%) 274 (55%) 
Pressure Ulcers   
No 748 (96%) 484 (97%) 
Yes 28 (4%) 17 (3%) 
Stamina – Hours of physical 
activities in the last 3 days 
  
Less than two hours 313 (40%) 184 (37%) 
Two or more hours 463 (60%) 317 (63%) 
Stair Climbing   
Without Help 283 (36%) 190 (38%) 
With Help / No Climb 493 (64%) 311 (62%) 
CPS Scale Mean Score: 
 0.61 ± 0.98 
Mean Score: 
0.48 (±0.92) 
0 (Intact) – (Reference) 486 (63%) 338 (67%) 
1-2 (Borderline intact – Mild 
impairment) 
244 (31%) 151 (30%) 
3-4 (moderate – Moderate severe 
impairment) 
39 (5%) 5 (1%) 
5-6 (Severe – Very severe 
impairment 
7 (1%) 7 (2%) 
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ADL Hierarchy Scale Mean Score: 
1.73 ± 1.83 
Mean Score: 
1.69 ± 1.86 
0 (Independent) – (Reference) 310 (40%) 216 (43%) 
1-2 (Supervision required – limited 
impairment) 
233 (30%) 138 (28%) 
3+ (Extensive assistance required – 
total dependence) 
233 (30%) 147 (29%) 
IADL Involvement Scale  Mean Score: 
11.96 ± 5.34 
Mean Score 
12.05 ± 5.64 
Pain Scale Mean Score: 
1.13 ± 1.10  
Mean Score: 
1.15 ± 1.15 
0 (No pain) – (Reference) 337 (44%) 221 (44%) 
1-2 (Less than daily pain – Daily 
pain not severe) 
374 (48%) 226 (45%) 
3+ (Daily severe pain) 65 (8%) 54 (11%) 
Depression Rating Scale Mean Score: 
1.62 ± 2.20 
Mean Score: 
1.58 ± 2.25 
0 -2 (No depression) 577 (74%) 380 (76%) 
3+ (Minor or Major Depression) 199 (26%) 121 (24%) 
CHESS Scale Mean Score: 
1.65 ± 1.01  
 Mean Score: 
 1.62 ± 1.02 
0 (Not at all unstable) – (Reference) 91 (12%) 58 (12%) 
1-2 (Little – Some instability) 518 (67%) 341 (68%) 
3+ (Moderately – Highly unstable) 167 (21%) 102 (20%) 
 
Univariate and Multiple Logistic Regression 
Predictors of receipt of riluzole are presented in Table 5. In the univariate analysis, 
older age, male gender, moderate – moderate severe impairment in cognitive functions and 
geographical locations across LHINs (Champlain, Erie St. Clair, Hamilton Niagara 
Haldimand Brant, North East, South East, and South West) reduced the likelihood of riluzole 
prescription. Being married was the only predictor associated with increased likelihood of 






Table 5: Univariate Logistic Regression Analysis 
Variables OR (95% CI) P-value 
Age 0.977 (0.968 – 0.987) <0.0001 
Gender 0.778 (0.620 – 0.976) 0.029 
Weight Loss 0.842 (0.646 – 1.099) 0.206 
Food Consumption: Ate one or fewer meals in 
at least 2 of the last 3 days 
1.232 (0.770 – 1.973) 0.384 
Difficulty Swallowing 1.008 (0.805 – 1.262) 0.947 
Falls Frequency 0.997 (0.795 – 1.249) 0.978 
Pressure Ulcers 0.939 (0.508 – 1.733) 0.840 
Stamina – Hours of physical activities in the 
last 3 days 
1.165 (0.924 – 1.468) 0.197 
Stair Climbing 0.940 (0.745 – 1.185) 0.599 
Marital Status 1.561 (1.215 – 2.005) 0.0005 
Availability of Caregiver 1.305 (0.951 – 1.792) 0.099 
Geographical Location   
Central East 1.039 (0.614 – 1.757) 0.888 
Central 1.135 (0.678 – 1.900) 0.630 
Champlain 0.224 (0.124 – 0.406) <.0001 
Central West 0.854 (0.433 – 1.685) 0.649 
Erie St. Clair 0.400 (0.201 – 0.797) 0.009 
Hamilton Niagara Haldimand Brant 0.528 (0.307 – 0.908) 0.021 
Mississauga Halton 0.638 (0.365 – 1.113) 0.113 
North East 0.397 (0.208 – 0.758) 0.005 
North Simcoe Muskoka 0.662 (0.319 – 1.373) 0.268 
North West 0.510 (0.197 – 1.322) 0.166 
South East 0.366 (0.185 – 0.725) 0.004 
South West 0.506 (0.285 – 0.898) 0.020 
Toronto Central (Reference)   
Waterloo Wellington 0.604 (0.313 – 1.166) 0.133 
CPS Scale   
0 (Intact) – (Reference)   
1-2 (Borderline intact – Mild impairment) 0.890 (0.696 – 1.138) 0.352 
3-4 (moderate – Moderate severe impairment) 0.184 (0.072 – 0.473) 0.0004 
5-6 (Severe – Very severe impairment 1.438 (0.500 – 4.137) 0.501 
ADL Hierarchy Scale   
0 (Independent) – (Reference)   
1-2 (Supervision required – limited impairment) 0.850 (0.647 – 1.117) 0.243 
3+ (Extensive assistance required – total 
dependence) 
0.905 (0.691 – 1.186) 0.471 
IADL Involvement Scale 1.003 (0.983 – 1.024) 0.778 
Pain Scale   
0 (No pain) – (Reference)   
1-2 (Less than daily pain – Daily pain not severe) 0.921 (0.727 – 1.168) 0.498 
3+ (Daily severe pain) 1.267 (0.850 – 1.888) 0.245 
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Depression Rating Scale 0.923 (0.712 – 1.198) 0.548 
CHESS Scale   
0 (Not at all unstable) – (Reference)   
1-2 (Little – Some instability) 1.033 (0.723 – 1.475) 0.859 
3+ (Moderately – Highly unstable) 0.959 (0.635 – 1.446) 0.840 
 
Table 6: Multiple Logistic Regression Analysis 
Variables OR (95% CI) P-value 
Age 0.975 (0.964 – 0.985) <.0001 
Gender  0.887 (0.691 – 1.140) 0.349 
Marital Status 1.637 (1.247 – 2.148) 0.0004 
Geographical Location   
Central East 0.878 (0.506 – 1.525) 0.645 
Central 0.940 (0.547 – 1.615) 0.822 
Champlain 0.189 (0.102 – 0.351) <.0001 
Central West 0.838 (0.411 – 1.708) 0.626 
Erie St. Clair 0.314 (0.154 – 0.644) 0.002 
Hamilton Niagara Haldimand Brant 0.412 (0.233 – 0.730) 0.002 
Mississauga Halton 0.536 (0.299 – 0.962) 0.037 
North East 0.300 (0.152 – 0.591) 0.0005 
North Simcoe Muskoka 0.580 (0.272 – 1.236) 0.158 
North West 0.489 (0.182 – 1.314) 0.156 
South East 0.311 (0.153 – 0.631) 0.001 
South West 0.417 (0.228 – 0.761) 0.004 
Toronto Central (Reference)   
Waterloo Wellington 0.504 (0.253 – 1.003) 0.051 
CPS Scale   
0 (Intact) – (Reference)   
1-2 (Borderline intact – Mild impairment) 0.974 (0.749 – 1.265) 0.842 
3-4 (moderate – Moderate severe impairment) 0.201 (0.076 – 0.530) 0.001 
5-6 (Severe – Very severe impairment 1.328 (0.437 – 4.034) 0.617 
In the multiple logistic regression analysis (shown in Table 6), four of five variables 
reached statistical significance. Older age, moderate – moderate severe impairment in 
cognitive functions and geographical locations across LHINs (Champlain, Erie St. Clair, 
Hamilton Niagara Haldimand Brant, Mississauga Halton, North East, South East, and South 
West) decreased the likelihood of riluzole prescription. Being married increased the 
likelihood of riluzole prescription. Gender was not considered as statistically significant in 
the multiple logistic regression analysis.  
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Figure 1: Odds ratio of riluzole prescription across each LHINs vs. Toronto Central Network 
 





 To our knowledge, this study is the first of its kind examining the predictors affecting 
the likelihood of receiving riluzole for the treatment of ALS. The results of this study show 
that the prevalence of riluzole use among ALS patients in Ontario home care setting was 
39.2%, which is relatively low considering the fact that riluzole is the only drug approved for 
the treatment of ALS.  
 According to the study results, younger patients were more likely to be prescribed to 
riluzole. Moreover, patients who were married were more likely to receive riluzole than 
patients who lived alone; this is despite the fact that patients who are older and living alone 
have worse prognosis than patients who are young and married, and thus may have more to 
gain from the medication (Chio et al., 2008). One explanation may be that older patients are 
more prone to drug adverse events and living with other comorbidities, which may 
discourage physicians from prescribing riluzole. 
 The results also showed that the likelihood of riluzole prescription is heavily 
dependent upon one’s geographical residency. Toronto Central was chosen as the reference 
group in this study as most academic institutions are concentrated in this area. Patients living 
further away from Toronto Central were less likely to be prescribed to riluzole. Nor do the 
results reflect the absence of ALS clinics, which are located in Hamilton (HNHB), Kingston 
(SE), London (SW), Ottawa (CHAM), Thunder Bay (NW), and Toronto (TC). The reason for 
this disparity cannot be explained with the current data. However, the results indicate that 
potential regional health inequities might be present for the treatment of ALS. As riluzole is 
proven to have modest benefits, it can be hypothesized that if a patient who is treated in an 
institution with more use of riluzole, then the institution is more likely to be using other best 
practices to manage ALS. However, using riluzole as a marker for care quality should be 
further investigated.   
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The present study had several limitations. As the data only captured information 
drawn from the initial admission assessments, the results do not reflect the use of riluzole 
throughout the entire home care stay. Secondly, as 1,277 out of 1,351 patients had 
information on the use of riluzole, 74 observations or 9.5% of the total population has been 
excluded from the study. Thus, the present study may have underestimated (or overestimated) 
the prevalence use of riluzole. Lastly, it is important to note that while all variables were 
carefully chosen in correlation to the prognostic factors identified in the literature, the study 
may not have captured all relevant variables that are related to the outcome. Moreover, the 
study did not account for the unmeasured covariates (e.g. income level, caregiver stress), 
which may play a critical role for the prescription of riluzole.   
 In conclusion, this study identified many important predictors associated with the 
receipt of riluzole, and thus target physicians and policymakers to promote the proper use of 
the drug. Patients’ characteristics such as older age, moderate cognitive score, not being 
married and geographical locations across LHINs decreased the likelihood of receiving 
riluzole. Further research on physician behaviors and routine clinical practices across LHINs 
are required to better understand the factors associated with the prescription of riluzole. In 
addition, further research is necessary on whether or not the use of riluzole is a marker of 














A retrospective cohort study of OACCAC-HC assessment data was carried out to 
perform the survival analysis in order to estimate the delay in care transitions in HC. 
Assessment data were collected at the time of admission and patients receive additional 
assessments approximately every six months. For cost analysis, cost information was derived 
from previously published journals and Canadian Institute for Health Information Patient 
Cost Estimator (CIHI-PCE). Although secondary data analyses pose several limitations, 
analyses through the availability of high quality clinical assessments, along with the long-
term observational data establishes a unique approach that has never been performed in cost-
effectiveness analysis for riluzole. 
 
Study Sample and Setting 
As the present study involved secondary data analyses, no subject recruitment was 
required. All subjects were drawn from the OACCAC-HC database, with specific focus on 
patients with diagnosis of ALS. The population that was examined in this study was Canadian 
long stay home care clients (those expected to be on service for 60 days or longer) diagnosed 
with ALS in the province of Ontario. Individuals receiving acute or palliative care do not 
receive RAI-HC assessments and rather, receive RAI-PC assessment and thus, these 
individuals were not included in this dataset. RAI-HC assessments for home care clients were 
collected between January 2002 and March 2015. However, from close consultation with a 
RAI data specialist, home care clients with RAI-HC assessment data from April 1
st
, 2005 to 
March 31
st
, 2013 were eligible for this study to compensate for the errors during the initial 
 
34 
implementation period and in correlation to the 2-year follow-up period that was used for this 
study. If the client had multiple assessments in that period, only the baseline assessment was 
used for the analyses. Approximately 60% of the study population had multiple assessments. 
Furthermore, patients who had a history of receiving a tracheostomy were not included in the 
study. 
  The data for this proposed study was provided by the OACCAC, which manages 
the RAI-HC database of home care clients within each of the Ontario Local Health 
Integration Networks (LHINs). RAI-HC is a standardized comprehensive assessment 
instrument that captures information regarding clients’ sociodemographic characteristics, 
clinical status, mental health status, psychosocial status, physical functions, medication use, 
and receipt of specific services (Morris, Fries, Morris, 1999). Since 2002, the RAI-HC 
assessment has been mandated for all long-stay home care clients with assessment data 
captured in OACCAC database.  
Embedded within the RAI-HC are scales that provide validated summary measures 
of individual functioning in specified clinical areas. In this study, seven validated scales that 
summarize functional status in cognition, ADLs, health instability, pain, and mood will be 
examined. The corresponding scales are Cognitive Performance Scale, Activities of Daily 
Living Self-Performance Hierarchy Scale, Instrumental Activities of Daily Living Scale, 
Changes in Health, End-stage Disease and Signs and Symptoms Scale, Pain Scale, 
Depression Rating Scale, and Method for Assigning Priority Levels scale.  
 Cognitive Performance Scale (CPS) is a combined measurement of memory 
impairments, level of consciousness, decision-making skills, and the ability to be understood 
by others (Morris et al., 1994). The scores range from 0 (intact) to 6 (very severe impairment). 
Previous studies have reported that CPS is highly correlated to the Mini-Mental State Exam 
(MMSE), which is a widely used test for cognition status that has been found to be both valid 
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and reliable (Morris et al., 1994).  
 Activities of Daily Living (ADL) Self-Performance Hierarchy Scale measure one’s 
physical functioning (e.g. dressing, eating, bathing, locomotion, etc.) using selected ADL 
items that represent stages of the disablement process. The scores range from 0 (independent) 
to 6 (total dependence), with the additional option where the activity did not occur (8), which 
is also coded as total dependence. While the ADL Self-Performance Hierarchy Scale was 
originally developed for use in the nursing homes, the instrument was proven valid and 
reliable in home care setting as well (Landi et al., 2000).  
 The Instrumental Activities of Daily Living (IADL) Involvement Scale is similar to 
ADL Hierarchy Scale as the instrument also measures one’s self-maintenance abilities. 
However, instead of measuring one’s physical functions, the Involvement Scale assesses 
functioning in routine activities around the home or in the community. The scale is composed 
of seven items: meal preparation, ordinary housework, managing finances, managing 
medications, phone use, shopping and transportation. These items are then summed to 
produce a score that ranges from 0 to 48 with higher scores indicating greater impairments.  
 The Pain Scale was developed using the Visual Analogue Scale (VAS) as the external 
standard due to its sensitivity of assessing multiple levels of pain (Fries, Simon, Morris, 
Flodstrom, & Bookstein, 2001). The scale assesses two items, which are pain frequency and 
pain intensity. In total, there are four levels, which are no pain (0), less than daily pain (1), 
daily pain but not severe (2), and daily severe pain (3). Once again, the scale was originally 
developed and highly predictive of pain for nursing home residents; however, the instrument 
has not yet been validated for home care population (Fries et al., 2001).   
The Depression Rating Scale (DRS) is composed of seven RAI-HC mood items, 
which are used for clinical assessments to screen for depression. These items are summed 
together to produce a score which ranges between 0 (no mood symptoms) to 14 (all mood 
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symptoms present). Scores of 3 or greater indicates major or minor depressive disorders. The 
scale was validated against the Hamilton Depression Rating Scale and the Cornell Scale for 
Depression, which are the current standard scales used for psychiatric research and dementia 
respectively.  
 The Changes in Health, End-Stage Disease and Signs and Symptoms (CHESS) Scale 
was developed to detect health instability and identify individuals at risk for serious decline 
in functions. The scale assesses nine items which include worsening of decision-making, 
decline in ADL, vomiting, edema, shortness of breath, end-stage disease, weight loss, 
dehydration, and leaving food uneaten. These items are summed to produce a 6-point scale, 
which ranges from 0 (not at all unstable) to 5 (highly unstable). The scale has been validated 
to be highly predictive of adverse outcomes such as mortality, hospitalization, pain, caregiver 
stress, and poor self-rated health (Hirdes, Frijters, & Teare, 2003).  
 The Methods for Assigning Priority Levels (MAPLe) scale was developed to be a 
predictor for institutionalization and used as an indicator for allocation of home care 
resources and prioritization among home care clients (Hirdes, Poss & Curtin-Telegdi, 2008). 
MAPLe is an internationally validated predictor of nursing home placements, caregiver 
distress, and ratings that client would be served better in another care setting (Hirdes et al., 
2008). The algorithm was derived from the MDC-HC data from Ontario, Canada and 
validated with samples of home care clients from three other provinces (British Columbia, 
Manitoba, and Nova Scotia) and five other countries (Iceland, Italy, Japan, Sweden, and 
United States) (Hirdes et al., 2008). The scale ranges from 1 (Low) to 5 (Very High).   
The University of Waterloo retains de-identified copies of OACCAC database as part 
of a license agreement between InterRAI and CIHI. Previous studies and reviews have found 
RAI instruments to be valid and reliable measures of patient characteristics (Hirdes, Poss, 




Propensity score is the probability of treatment assignment dependent upon patients’ 
observed baseline characteristics (Austin, 2011; Rosenbaum & Rubin, 1984). Propensity 
score is a balancing score which measures the likelihood that a patient would have been 
treated using only their covariate scores (Austin, 2011; Rosenbaum & Rubin, 1984). In most 
cases, randomized clinical trials are the gold standard approach in determining the efficacy of 
a drug on outcomes. The randomization ensures no selection bias and thus, there are no 
systematic differences in observed and unobserved covariates between the comparison groups 
(Austin, 2011). Since the OACCAC-HC is an observational database, adjustments for 
potential bias due to the confounding variables are required since assignments of riluzole 
cannot be assumed to be random. Hence, measurement of the propensity score allowed the 
study to create a quasi-experiment, which reduced the possibility of bias. 
 
Measurements 
Data for diagnosis, outcome, exposure, and other clinical assessment variables were 
drawn from the OACCAC-HC database. The diagnosis of interest was ALS, while the main 
outcome of interest was the time to discharge from home care, which included death, 
placement into long-term care, and hospitalization. Moreover, exposure of interest was the 
prescription for riluzole (riluzole vs. no riluzole), while clinical assessment variables were 
those suspected to be the predictors of outcome.   
In order to calculate the propensity score, observed covariates that affect both 
treatment selection and outcome were first identified (Stuart, 2010). These variables were 
chosen in correlation to the prognostic factors that were identified earlier in the literature 
review section. The independent variables that were included in this section mirror much of 
the variables that were included in Chapter 4 of this thesis. However, as Bryson, Dorsett & 
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Purdon (2002) pointed out that having too many variables may increase variance in the 
propensity score calculation, individual items such as food consumption, difficulty in 
swallowing, falls frequency, pressure ulcers, stair climbing, and stamina were replaced with 
Methods for Assigning Priority Levels (MAPLe) scale, which is a scale that incorporates the 
aforementioned variables into its scoring criteria.  
The following RAI-HC items were examined for estimating propensity score: clients’ 
sociodemographic status (age, gender, geographical location); psychosocial characteristics 
(marital status & availability of caregiver); health status (cognitive impairments, functional 
impairments, health instability, pain, depression, prioritization level); and medication use 
(riluzole). 
   
5.2 Analysis 
Software 
 All statistical analyses for this study were carried out using Statistical Analysis 
Software (SAS), Version 9.4 (SAS Institute, Cary, NC, USA). 
 
Ethics Approval  
 This project was cleared for ethics by the Office of Research Ethics at the University 
of Waterloo on 01 December 2016; ORE #: 21894. 
            
Estimation of Propensity Score 
 Once the variables had been selected, multivariate logistic regression was used to 
estimate the propensity scores. The covariates were used in a logistic regression to predict the 
exposure of interest (riluzole vs. non-riluzole), excluding the outcome, which is the time to 
discharge from home care. Hence, dependent variable was the treatment group (1 = treatment, 
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0 = control), while independent variables were the observed baseline covariates. Essentially, 
all the variables that were included in the model were collapsed into a ‘single’ variable, which 
is the probability of being exposed to the treatment: propensity scores. 
 
Adjustments 
Once the propensity score has been estimated, stratification was used to adjust for the 
covariates prior to estimating the treatment effect. Stratification consisted of grouping 
subjects into strata by estimated propensity scores and allowed for direct comparison of 
treated and control subjects in the same strata. Previous research suggests that creating five 
strata based on the propensity score removes approximately 90% of bias in all covariates 
when estimating a linear treatment effect (Rosenbaum & Rubin, 1984). Hence, subjects were 
stratified into five, approximately equally sized quintiles from the estimated propensity score.  
To show that the propensity scores removed any bias due to covariate differences 
across the two treatment groups, bivariate tests were conducted for each covariate prior to 
propensity score estimation. T-tests were conducted for continuous variables and chi-square 
tests were conducted for categorical variables. Then, the GLM procedure was used to 
calculate the least square means and corresponding p-values for each covariate adjusted for 
propensity scores, which were used to assess the differences between the treatment groups 
before and after stratifying subjects by the propensity scores. Moreover, interaction plots for 
each variable were constructed to assess balance across all propensity score quintiles.  
 
Survival Analysis 
Kaplan-Meier (K-M) survival curves were constructed separately for treated and 
untreated groups in each propensity score stratum to assess the time to discharge over 2-year 
period. To estimate the effect of treatment in the overall population (Average Treatment 
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Effect), each stratum was weighted by the number of subjects within the stratum, in order to 
create a pooled analysis of stratum-specific K-M curves to obtain a population-average 
survival curve. Cox proportional hazards regression model was used to produce hazard ratios 
by using treatment status and propensity score quintiles as covariates. 
 
Cost Analysis 
As this study was conducted using the health services perspective (Ministry of Health 
and Long-Term Care), only direct costs were considered in the cost analysis. Direct costs 
included in this study were: cost of standard supportive home care services, which consists of 
nursing visits, shifts nursing hours, personal support hours, physical therapy visits, 
occupational therapy visits, speech language therapy visits, social work visits, dietician visits 
and administration of 100 mg of riluzole on daily basis. Moreover, estimated average costs 
for staying in long-term care and hospital after discharge from home care was used as a cost-
offset factor. Costs were adjusted for inflation to 2016 Canadian dollars using the consumer 
price index for healthcare in Ontario. Moreover, annual discount rate of 3% was applied to 
both benefits and costs as suggested by the WHO Guideline to Cost-Effectiveness Analysis. 
Indirect medical costs were not included as they were not relevant to the perspective of this 
analysis. The cost estimates were derived from information published in multiple sources 
including CIHI-PCE and relevant literatures. 
 To evaluate the cost-effectiveness of riluzole therapy compared to standard 
supportive care therapy, the incremental cost effectiveness ratio (ICER) per life-year gained, 
that is, the difference in cost between riluzole therapy (including cost-offset factors) and 
standard care therapy divided by the difference in median survival was calculated as follows: 
ICER = (CostRiluzole - CostStandardTherapy) / (SurvivalRiluzole - SurvivalStandardTherapy). 
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In addition to calculating the ICER per life-year gained, incremental cost per quality-adjusted 
life years (QALY) gained was measured. Health state utility scores that were required to 
measure the QALYs were derived from information published in the relevant literatures that 
assessed the utility scores in each stages of ALS. 
 
Sensitivity Analysis: 
 One-way deterministic sensitivity analyses were carried out in a ± 20% range of each 
base case parameters, which included all costs, health utility scores, and survival differences 
(time to discharge from home care). In addition, scenario analyses were conducted by 
constructing best and worst case scenarios, which involved alterations of multiple parameters 
simultaneously. The best case scenario involved changing parameters in the most optimistic 
way to produce the most favorable ICER, whereas the worst case scenario involved changing 




From a total of 1,351 patients diagnosed with ALS, 1,277 patients had information on 
the use of riluzole. Demographics of study participants are summarized in Table 7.  
  
Table 7: Demographic characteristics of the study population 
Baseline Characteristics No-Riluzole 
(n = 776) (%) 
Riluzole 
(n = 501) (%) 




18 – 45  36 (5%) 34 (7%) 
46 – 55 91 (12%) 75 (15%) 
56 – 65 194 (25%) 159 (32%) 
66 – 75 244 (31%) 151 (30%) 
>75 211 (27%) 82 (16%) 
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Gender   
Male 401 (52%) 290 (58%) 
Female 375 (48%) 211 (42%) 
Marital Status (Married)   
Not Married 267 (34%) 126 (25%) 
Married 509 (66%) 375 (75%) 
Availability of Caregiver   
Living Alone 132 (17%) 68 (14%) 
Living with spouse or others 644 (83%) 433 (86%) 
Geographical Location   
Central East 70 (9%) 76 (15%) 
Central 75 (10%) 89 (17%) 
Champlain 111 (14%) 26 (5%) 
Central West 28 (4%) 25 (5%) 
Erie St. Clair 43 (5%) 18 (4%) 
Hamilton Niagara Haldimand Brant 87 (11%) 48 (10%) 
Mississauga Halton 69 (9%) 46 (9%) 
North East 53 (7%) 22 (4%) 
North Simcoe Muskoka 26 (3%) 18 (4%) 
North West 15 (2%) 8 (2%) 
South East 47 (6%) 18 (4%) 
South West 79 (9%) 37 (7%) 
Toronto Central 44 (6%) 46 (9%) 
Waterloo Wellington 38 (5%) 24 (5%) 
  
Overall, study participants were more likely to be males than females, which is 
consistent with other studies that reported the incidences of ALS are more common in men. 
Majority of the study populations were over 55 years of age with the mean age of 67 years 
old in the non-riluzole group and 63 years old in the riluzole group. The proportions of 
subjects who were married were higher in the riluzole group than the non-riluzole group.  
Table 8: Summary of clinical characteristics 
Baseline Characteristics No-Riluzole 
(n = 776) (%) 
Riluzole 
(n = 501) (%) 
CPS Scale Mean Score: 
 0.61 ± 0.98 
Mean Score: 
0.48 (±0.92) 
0 (Intact) – (Reference) 486 (63%) 338 (67%) 
1-2 (Borderline intact – Mild 
impairment) 
244 (31%) 151 (30%) 
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3-4 (moderate – Moderate severe 
impairment) 
39 (5%) 5 (1%) 
5-6 (Severe – Very severe 
impairment 
7 (1%) 7 (2%) 
ADL Hierarchy Scale Mean Score: 
1.73 ± 1.83 
Mean Score: 
1.69 ± 1.86 
0 (Independent) – (Reference) 310 (40%) 216 (43%) 
1-2 (Supervision required – limited 
impairment) 
233 (30%) 138 (28%) 
3+ (Extensive assistance required – 
total dependence) 
233 (30%) 147 (29%) 
IADL Involvement Scale  Mean Score: 
11.96 ± 5.34 
Mean Score 
12.05 ± 5.64 
Pain Scale Mean Score: 
1.13 ± 1.10  
Mean Score: 
1.15 ± 1.15 
0 (No pain) – (Reference) 337 (44%) 221 (44%) 
1-2 (Less than daily pain – Daily 
pain not severe) 
374 (48%) 226 (45%) 
3+ (Daily severe pain) 65 (8%) 54 (11%) 
Depression Rating Scale Mean Score: 
1.62 ± 2.20 
Mean Score: 
1.58 ± 2.25 
0 -2 (No depression) 577 (74%) 380 (76%) 
3+ (Minor or Major Depression) 199 (26%) 121 (24%) 
CHESS Scale Mean Score: 
1.65 ± 1.01  
 Mean Score: 
 1.62 ± 1.02 
0 (Not at all unstable) – (Reference) 91 (12%) 58 (12%) 
1-2 (Little – Some instability) 518 (67%) 341 (68%) 
3+ (Moderately – Highly unstable) 167 (21%) 102 (20%) 
MAPLe Scale Mean Score: 
3.03 ± 1.16 
Mean Score: 
2.92 ± 1.18 
1 (Low) 149 (19%) 111 (22%) 
2 – 3 (Mild – moderate) 304 (39%) 194 (39%) 
4 – 5 (High – very high) 323 (42%) 196 (39%) 
 
Table 8 depicts the clinical characteristics of the study population. Patients in the 
riluzole group were less likely to have moderate – moderately severe impairment in cognitive 
functions than the non-riluzole group. Otherwise, the overall clinical statuses between the two 





Table 9: Discharge Reasons from Home Care 
 Discharge Reasons 
 Death Long-Term Care Hospitalization Others 
No Riluzole N = 348  
(44.85%) 
N = 59 
(7.60%) 
N = 121 
(15.59%) 
N = 248 
(31.96%) 
Riluzole N = 254 
(50.70%) 
N = 33 
(6.60%) 
N = 61 
(12.18%) 
N = 153 
(30.52%) 
 
Table 9 depicts the proportion of discharge reasons across the two treatment groups. 
More patients who were taking riluzole were discharged from home care due to death. 
Approximately same amount of patients were placed into long-term care, while more patients 
who were not taking riluzole were hospitalized compared to patients who were taking riluzole. 
Reasons for discharge from home care other than death, placement into long-term care, or 
hospitalization include: completion of service plan, transfer to other CCAC, client preference, 
opted for other community services, and vacation over 30 days.   
  
Propensity Score 
 Propensity scores for each individual were calculated by fitting a logistic regression 
model to estimate all covariates shown in demographic profiles and clinical characteristics 




Figure 3: Histogram - Distribution of Propensity Score by Treatment Group 
 




Histogram and boxplot shown in Figure 3 and Figure 4 depicts the distribution of 
propensity score by treatment group, which shows that propensity score in the riluzole group 
was higher than the non-riluzole group, with mean score of 0.41 and 0.38 respectively. The 
propensity scores vary from 0.16 to 0.68 and there is a good degree of overlap across the two 
treatment groups.  
 
Propensity Score Adjustments 
Propensity score stratification was used as an adjustment method for this study. 
Based on each patient’s respective propensity score, all individuals were ranked and stratified 
into five quintiles in an increasing order. Quintile 1 represents those with the lowest 
propensity scores, while quintile 5 represents those with the highest propensity scores. As 
shown in figure 5, the propensity scores between treatment groups are very similar to one 
another in each of the quintiles. 
Results from bivariate tests and GLM procedure are shown in Table 10. Mean value 
for each variable along with p-values for both treatment groups prior to propensity score 
estimation and least square means and p-values adjusted for propensity scores are reported in 
the table. Results indicate that age (p=<.0001), gender (p=0.029), geographical locations 
(p=<0.0001), marital status (p=0.0005), and CPS (p=0.0008) had statistically significant 
differences across the two treatment groups. However, adjusted p-values for all the 
aforementioned variables are >0.05, indicating that differences among the two treatment 
groups are no longer statistically significant. Moreover, mean value for each covariate was 
widely different across the two treatment groups prior to propensity score estimation. 
However, least mean squares adjusted for propensity scores indicate that mean value for each 
covariate are very similar across the two treatment groups.  
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In addition, interaction plots were constructed to assess balance across all five 
quintiles. Results from the interaction plots, as depicted in Figure 6 – Figure 17, show that 













Table 10: Covariates Balance Before and After Propensity Score 
 Before After 
 Treatment Group 
(Mean) 
 Treatment Group 
(Least Squared Mean) 
 
Variable No Riluzole Riluzole P-Value No Riluzole Riluzole P-Value 
Age 66.63 63.36 <0.0001 65.61 64.93 0.1749 
Gender 1.48 1.42 0.029 1.46 1.45 0.920 
Geographical Location 7.27 7.09 <0.0001 7.21 7.18 0.882 
Marital Status 0.66 0.75 0.0005 0.69 0.69 0.944 
Availability of Caregiver 0.83 0.86 0.099 0.84 0.84 0.971 
CPS Scale 0.61 0.48 0.0008 0.56 0.56 0.891 
ADL Hierarchy Scale 1.74 1.69 0.226 1.73 1.71 0.837 
IADL Involvement Scale 11.96 12.05 0.779 11.99 12.02 0.921 
Pain Scale 1.13 1.15 0.413 1.13 1.14 0.874 
Depression Rating Scale 1.63 1.58 0.383 1.62 1.59 0.836 
CHESS Scale 1.65 1.62 0.176 1.64 1.63 0.925 





Figure 6: Interaction Plot – Age 
 




Figure 8: Interaction Plot – Geographical Location 
 




Figure 10: Interaction Plot – Availability of Caregiver 
 




Figure 12: Interaction Plot – ADL Self-Performance Hierarchy Scale 
 




Figure 14: Interaction Plot – Depression Rating Scale 
 




Figure 16: Interaction Plot – CHESS Scale 
 




 Kaplan-Meier survival curves were constructed in order to estimate the stratum-
specific average time to discharge. Figure 18 depicts the stratum-specific Kaplan-Meier 
survival curves for riluzole and non-riluzole subjects across the five propensity score strata. 
The stratum-specific survival estimates were used to construct pooled Kaplan-Meier survival 
curves to estimate the overall measure of treatment effect across the two treatment groups, as 
shown in Figure 19.  
The average stratum-specific 2-year mortality (time to discharge) in patients not 
receiving riluzole was 268, 291, 340, 382, and 360 days for strata 1,3,5,7, and 9, respectively. 
The average stratum-specific 2-year mortality (time to discharge) in patients receiving 
riluzole was 305, 342, 342, 380, and 427 days for strata 2,4,6,8, and 10, respectively. The 
weighted mean of the stratum-specific 2-year mortality for patients not taking riluzole was 
321 ± 22 days and 366 ± 25 days for patients taking riluzole. Thus, patients who were taking 
riluzole, on average, stayed 45 days longer in home care than patients who were not taking 
riluzole.  
 When a Cox proportional hazard model that stratified on the five propensity score 
quintiles was used, the estimated hazard ratio was 0.86 (95% confidence interval: 0.745 – 
0.997). Thus, receipt of riluzole reduced the hazard of death, placement into long-term care, 




Figure 18: Stratum-Specific Kaplan-Meier Survival Curve 
 





 A thesis paper by Clare Cheng at the University of Waterloo has estimated that the 
weekly cost of home care in Ontario for ALS population was $934.96 per week or $48751.49 
per year (Cheng, 2013). According to the Ontario Drug Benefits Program, the price of generic 
versions of riluzole, manufactured by either Apotex Inc., or Mylan Pharmaceuticals Inc. was 
$7.36 per tablet of 50mg, which results in $14.72 per day in accordance to the recommended 
dosage per day of 100mg/day. The annual price of riluzole was $5372.80.  
While the proportion of the study population discharged to long-term care was 
equivalent across the two treatment groups, riluzole delayed hospitalization in approximately 
3.5% of the total population receiving the drug, which was considered as a cost-offset factor. 
The cost of hospitalization of ALS was derived from information published in the CIHI 
patient cost estimator with an estimated average cost of $15,305 per patient per stay. Thus, 
the cost-saving associated with riluzole in correlation to delay in hospitalization by 45 days 
for 3.5% of the population receiving the drug was $302.12. 
The corresponding ICER was calculated as follows: 
Table 11: Inputs for incremental cost-effectiveness ratio 
Parameter Value 
Cost of Home Care $48,751.49 
Cost of Medication $5372.80 
Hospitalization Cost-Offset $302.12 





The resulting ICER was $41,128.85 per LYG.  
 In order to calculate the ICER per quality-adjusted life year gained, health utility 
scores were derived from a previously published literature, which identified stage-specific 
health utility scores for ALS patients using Amyotrophic Lateral Sclerosis Assessment 
Questionnaire (ALSAQ-40) and EuroQol EQ-5D (Kiebert et al., 2001). As most patients with 
ALS in home care were considered to be in mild-moderate stages of ALS, this study assumed 
a health utility score of 0.74 during the entire duration of the home care stay. In addition, this 
study assumed that patients in the riluzole group gained additional 45 days, while maintaining 
a health utility score of 0.74. Furthermore, an assumption was made where patients 
discharged to long-term care or CCC from both treatment groups would survive equally long 
with the same quality of life scores.  
 
The resulting ICER was $55,579.53 per QALY. 
 
Sensitivity Analysis 
 One-way deterministic sensitivity analysis was conducted for the majority of 
parameters using a range of ± 20% to examine their effects on the ICER. The inputs for the 
one-way sensitivity analysis are shown in Table 12. 
The results of the one-way sensitivity analysis are shown in Figure 20, which depicts 
graphically how variations in each parameter affect the ICER. The tornado diagram is stacked 
in decreasing width, indicating that change in parameter at the top (health utility score) have 
the greatest effect on the ICER, while change in parameter at the bottom (cost of 
hospitalization) have the least impact on the ICER.   
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Table 12: Inputs for one-way sensitivity analysis 
Inputs Base Upper Range Lower Range 
Cost of Medication $5372.80 $6,447.36 $4,298.24 
Health Utility Score 0.74 0.89 0.59 
Cost of Hospitalization $302.12 $362.54 $241.70 
Survival Difference 45 days 54 days 36 days 
 
Figure 20: Tornado Diagram 
 
To estimate how the ICER might change due to alterations in multiple parameters 
simultaneously, best and worst case scenarios were determined. Inputs included in the 
scenario analyses involved alterations in all four parameter using the values derived from the 
one-way deterministic sensitivity analyses. Best case scenario involved upper range values 
for health utility score & survival differences and lower range values for cost of medication & 
cost of hospitalization. Worst case scenario involved upper range values for cost of 
medication & cost of hospitalization and lower range values for health utility score & 
survival differences. Parameter values for both scenarios are depicted in Table 13.  
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Table 13: Inputs for Scenario Analysis 
Inputs Base Case Best Case Worst Case 
Cost of Medication $5,372.80 $4,298.24 $6,447.36 
Health Utility Score 0.74 0.89 0.59 
Cost of Hospitalization $302.12 $362.54 $241.70 
Time to Discharge 45 Days 54 Days 36 Days 
 
Best Case Scenario: 
 
Resulting ICER was $29,890.36 per QALY. 
 
Worst Case Scenario:  
 
Resulting ICER was $106,641.52 per QALY 
 
5.4 Discussion 
 The results of the primary analysis showed that administration of riluzole in patients 
with ALS in home care involved a cost of approximately $41,000 per life-year gained or 
$55,000 per quality-adjusted life year gained. Considering that the willingness-to-pay 
threshold is around $50,000 per QALY, the results of this study suggest an unfavorable cost-
effectiveness for riluzole, or at best, a borderline value for cost-effectiveness. However, 
considering the rare nature of ALS and the fact that riluzole is the only approved medication 
for the treatment of ALS; the cost implication is not too unreasonable. 
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 Over the course of undertaking deterministic sensitivity analyses, the resulting 
ICERs ranged from approximately $50,000 per QALY to $78,000 per QALY, reflecting the 
ICER’s sensitivity to parameters of health utility score, survival difference, and the cost of 
administration of riluzole. In the scenario analyses where multiple parameters were altered 
simultaneously, the ICERs were $29,890.36 per QALY and $106,641.52 per QALY for the 
best and worst case scenarios, respectively. Results from the scenario analyses indicate the 
possibility that riluzole is either cost-effective or exceed the willingness-to-pay threshold. 
 An interesting finding in the present study was that patients who are older and living 
alone were less likely to receive riluzole. However, the results from the survival analysis 
indicated that patients who are older and not married had more to benefit from the use of 
riluzole.  
 The present study has several limitations. Firstly, RCTs are the gold standard study 
design used to accurately assess the efficacy of the drug on outcomes. The random treatment 
allocation ensures that outcome statuses are not confounded by measured or unmeasured 
baseline characteristics, which allows the study to estimate the treatment outcome by directly 
comparing the control and treatment subjects. However, as the OACCAC-HC data is 
observational, it posed risks of bias as treatment selection may have been influenced by 
subject characteristics. Although propensity scores were calculated in attempt to minimize the 
bias, it did not account for bias resulting from the unobserved covariates, which may have 
influenced treatment selection. 
 Secondly, as this study only considered initial admission assessments for further 
statistical analyses, there may have been some bias in the survival estimates. As over 60% of 
the study population had multiple assessments, it is possible that individuals may not have 
been on riluzole during their initial assessments, but have been prescribed afterwards. 
Moreover, as the data do not indicate the initial date of diagnosis for ALS or initial 
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prescription date of riluzole, it is unclear how long patients had been exposed to the disease 
or how long they had been on riluzole prior to receiving home care services. Hence, an 
assumption was made where all ALS patients in home care were in their early stages, which 
resulted in utilizing a health utility score that corresponded to mild-moderate stages of ALS.   
 There were other approximations made in the economic estimations for this study. 
Firstly, cost of hospitalization for ALS patients in Canada was not available. The cost was 
derived from the CIHI patient cost estimator – Neuromuscular disorder, as information on 
ALS case mix group was not available in the CIHI-PCE. Therefore, neuromuscular disorder 
case mix group was chosen as it was the most relevant disease category next to ALS. 
Furthermore, an assumption was made where both treatment groups would survive equally 
long with the same utility score after discharging from home care. Thus, the cost of 
hospitalization and the utility score was assumed to be the same for the two treatment groups.  
 The results of this study differ from results found in the four previous cost-
effectiveness analyses of riluzole. In the two studies conducted by Ginsberg & Lev and 
Tavakoli et al., riluzole was found to be cost effective with ICERs of $12,013 USD ($15,743 
CAD) per LYG or $18,027 USD ($23,612 CAD) per QALY and $20,908 USD ($27,401 CAD) 
or $28,451 USD ($37,286 CAD) per QALY, respectively. On the other hand, studies 
conducted by Messori et al., and Gray found riluzole to be not cost effective with ICERs of 
$62,609 USD ($82,052 CAD) per LYG or $90,514 USD ($118,623 CAD) per QALY and 
$49,200 USD ($64,479 CAD) per LYG or $73,416 USD ($96,215 CAD) per QALY, 
respectively.  
 One possible reason for the difference in the ICER estimates may be due to the 
variations in the survival estimates. For example, the present study found that riluzole was 
associated with 1.5 months of survival gain in home care, which is relatively less compared 
to the study conducted by Tavakoli et al., which reported that riluzole was associated with 6.3 
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months of survival gain. Ginsberg & Lev estimated that riluzole prolonged life by 
approximately 3 months, while Gray reported that riluzole was associated with additional 1.1 
months in survival gains.   
 Another possible reason may be the health utility scores that were used to develop 
the ICERs per QALY. The present study assumed utility score of 0.74 for both treatment 
groups during the entire duration of home care stay as no information on disease stages were 
available. However, other studies have examined the benefits associated with riluzole over 
the entire course of the disease, incorporating stage-specific utility scores. 
 Lastly, the differences in the ICERs may well be explained by the components 
included in the cost analysis. As this study solely focused on ALS patients in home care 
setting, direct costs included standard supportive care, medication, and cost-savings from 
delay in hospitalization. However, as other studies have conducted cost-analyses accounting 
for the entire course of the disease, cost components included costs of outpatient visits, ALT 
testing, and medical procedures such as tracheostomy, jejunostomy, and gastrostomy, which 
are all relevant for patients who are in more advanced stages of ALS. Furthermore, it is 
important to note that previous studies were conducted in different parts of the world (Italy, 
Israel and UK). Therefore, the cost of administration of riluzole and the types of medical 
services in routine clinical practice may differ in different countries. 
 It is worth mentioning that this study was the first of its kind conducting cost-
effectiveness of riluzole using an observational database. The present study benefitted from 
the total sample of 1,351 populations, which is by far the largest cohort size that was used to 
assess the cost-effectiveness of riluzole. However, figures presented in this study are only 
illustrative rather than an exact measurement and thus, these results should only be used as a 
guide to aid in the decision-making process. With an ICER of $55,579.53 per QALY, cost-
effectiveness of riluzole is not too unreasonable considering the fact that it is a therapeutic 
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area with relatively small numbers of patients and where no alternative therapy exists. 
 Future studies should investigate the cost-effectiveness of riluzole in nursing homes 
and complex continuing care using observational data to better understand the benefits 
associated with riluzole in more advanced ALS patients. Moreover, direct costs and indirect 
costs associated with the management of ALS in Canada should be quantified. Lastly, 
information on quality of life in correlation to disease progressions should be better 
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APPENDIX A: Management and Assistance 
 
 
Stage Effects Supportive Treatment Time spent in stage 
(median duration 
in months) 
1 - Muscle cramping and 
fasciculation 
- Fatigue, poor balance, 
slurred speech, weak grip, 
tripping during walking 
- Help with minor physical 
tasks 
- Tools & devices (canes, 
leg brace) to aid daily 
functions 
18.1 
2 - Muscle paralysis 
- Contractures and joint pain 
- Chocking and difficulty 
eating from weakness in 
swallowing muscles 
- Respiratory insufficiency 
from weakness in breathing 
muscles 
- Range-of-motion exercise 
to help keep joints limber 
- Splints to help extremities 
remain stretched 
- Feeding tubes 
- Noninvasive ventilation 
-Equipment to aid physical 
function (e.g. wheelchair) 
5.5 
3 - Muscle paralysis (all 
voluntary muscles) 
- Unable to breathe without 
ventilator 
- Fatigue, headaches, and 
susceptibility to pneumonia 
- Unable to speak 
- Eating and drinking are 
impossible by mouth 
- Motor wheelchair 
- Hospital bed 
- Mechanical lift 
- Communication devices 
- Noninvasive or invasive 
(tracheostomy) ventilation 
- Feeding tube 
- Urinary catheters 
6.7 
4 - Disability to use lung 
muscles 
- Inability to swallow from 















JANUARY, 1999 Rhone-Poulenc Rorer, Inc. merged with Hoescht AG to form Aventis, 
Ltd.  
JANUARY, 2003 Implax Labs acquired FDA approval of its generic version of Rilutek-
50mg, but has been unable to sell the product since that time due to an 
injunction entered in patent litigation with Aventis. 
AUGUST, 2004 Aventis, Ltd. merges with Sanofi-Synthélabo to form Sanofi-Aventis. 
APRIL, 2013 Switzerland-based specialty pharmaceutical company, Covis Pharma 
Sarl, announced its agreement with Sanofi-Aventis U.S. LLC to 
acquire rights to Rilutek 
JUNE, 2013 Patent expiration of Rilutek. 
FDA granted approval to three companies to market generic versions 
of Riluzole (Sun Pharmaceutical Industries Ltd., Apotex Inc., and 
Glenmark Generics Inc.) 
JULY, 2013 FDA granted approval to Mylan Pharmaceuticals Inc. to market 
generic version of Riluzole 









POPULATION Patients diagnosed with ALS 
INTERVENTION Administration of riluzole with an objective 
to delay the onset of ventilator-dependence or 
tracheostomy-free survival 
COMPARATORS All comparators were considered eligible for 
inclusion, including any of the interventions 
in comparison with each other or versus no 
treatment or usual supportive care therapy 
OUTCOMES Cost effectiveness (both incremental cost and 
incremental effectiveness) was included 
DESIGN Economic evaluation: cost-effectiveness, 
cost-utility, cost-benefit, cost-minimization, 
cost-consequence were all considered 
eligible.  
 
Search strategy for literature review: 
 
PubMed 
Search (cost effective* OR cost analysis OR cost utility OR cost benefit analysis OR 
economics OR pharmacoeconomics OR quality-adjusted life year OR survival gain* OR 
drug costs OR costs and cost analysis OR cost OR costs) AND (riluzole OR rilutek) 
Filters 
Scopus 
( TITLE-ABS-KEY ( cost  OR  costs  OR  "quality adjusted life year"  OR  "cost 
effective"  OR  economics  OR  pharmacoeconomics  OR  economic*  OR  "surviva
l gain*"  OR  "cost utility"  OR  "cost benefit" )  AND  TITLE-ABS-






APPENDIX D: Care Facilities 
 
 




Description Care facility publicly 
funded in Ontario that 
provides assistances 
in health and social 
services to help 
patients with health 
conditions that 
prohibits them from 
carrying on their 
normal activities of 
daily living. Home 
care is mainly focused 
on prevention and 
maintenance and can 
be a substitute for 
acute-care or long-
term care facility. 
Care facility specifically 
designed for patients with 
complex medical needs 
who require supportive 
living and 24 hour on-site 
nurse assessments. Most 
patients in LTC are those 
with health conditions that 
undergo frequent 
fluctuation and require 
immediate health 
professional assessments. 
Care facility for patients 
whose current health 
conditions cannot be 
cared for in the 
community or long-term 
care facility. CCC is 
designed as a time–
limited in-hospital care 
to help with complex 
disease management 
and restorative care. 
Moreover, CCC 
provides supportive 
end-of-life care to 
optimize quality of life 








- Speech therapy 
- Social work services 
- Dietitian services 
- Personal support 
services 
- Nursing services (24 
hour on-site) 
- Tailored personal support 
based on patients’ assessed 
needs 
- Medical management 
- Wound care 
- Social work services 
- Accommodation and 
furnishing 
- Meals and housekeeping 
recreation 
- Medication management 
- Rehabilitation services 
- Dietitian services 
- End of life care needs 
 
- Complex medical 
service 
- Rehabilitation service 
- Palliative care service 
- Respite service 
- Nursing aide 
- Therapeutic services 
- Technological services 
- Recreation therapy 
- Physiotherapy 
- Occupational therapy 
- Speech language 
pathology 
- Spiritual care 
- Nutritional services 
- Personal support 
services 
- Social work services 
- Wound care 
ALS Stage Mild (1) to  
Moderate (2) 
Severe (3) to  
Palliative (4) 
Severe (3) to  
Palliative (4) 





APPENDIX E: CCAC/LHIN Map 
  
 
(Community Care Access Centres, n.d.) 
1. Erie St. Clair  
2. South West  
3. Waterloo Wellington  
4. Hamilton Niagara Haldimand Brant  
5. Central West  
6. Mississauga Halton  
7. Toronto Central  
8. Central  
9. Central East  
10. South East  
11. Champlain  
12. North Simcoe Muskoka  
13. North East  
14. North Wes 
